Collagenase clostridium histolyticum OK in Peyronie's

April 26, 2013
Collagenase clostridium histolyticum OK in peyronie's
For patients with Peyronie's disease, treatment with collagenase clostridium histolyticum intralesional injections is efficacious and tolerable, according to research published online Feb. 1 in The Journal of Urology.

(HealthDay)—For patients with Peyronie's disease, treatment with collagenase clostridium histolyticum (CCH) intralesional injections is efficacious and tolerable, according to research published online Feb. 1 in The Journal of Urology.

Martin Gelbard, M.D., from the Urology Associates Medical Group in Burbank, Calif., and colleagues examined the clinical efficacy and safety of CCH intralesional injections among patients with Peyronie's disease (417 and 415 patients in Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies [IMPRESS] I and II, respectively). CCH injections were given through a maximum of four treatment cycles, each separated by six weeks, with two injections per cycle.

Based on meta-analysis of data from the two studies, the researchers found that patients treated with CCH experienced a mean 34 percent improvement in penile curvature deformity, compared with a mean 18.2 percent improvement seen in placebo-treated individuals (P < 0.0001). In CCH-treated versus -treated individuals, the mean change in Peyronie's disease bother score was significantly improved. There were three corporal rupture serious adverse events, all of which were repaired surgically.

"The IMPRESS I and II studies support the clinical efficacy and safety of CCH treatment for both the physical and psychological aspects of Peyronie's disease," the authors write.

Several authors disclosed financial ties to Auxilium Pharmaceuticals, which funded the study and manufactures and markets CCH.

Explore further: Latrepirdine not effective in Huntington's disease

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Latrepirdine not effective in Huntington's disease

November 1, 2012
(HealthDay)—Although safe and well tolerated, the experimental small molecule latrepirdine does not improve cognition after six months of treatment in patients with mild-to-moderate Huntington's disease (HD), according ...

Corticorelin acetate has steroid-sparing effect in brain cancer

February 6, 2013
(HealthDay)—Corticorelin acetate (CrA) administration to patients with peritumoral brain edema (PBE) allows the reduction of steroid doses and is associated with reduced incidence and severity of steroid-induced myopathy ...

R.E.N.A.L. nephrometry score predicts treatment efficacy

December 27, 2012
(HealthDay)—The R.E.N.A.L. (radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior and location relative to polar lines) nephrometry scoring system predicts the efficacy of treatment and ...

Long-term ranibizumab beneficial for macular edema

October 11, 2012
(HealthDay)—Long-term aggressive treatment of patients with macular edema with ranibizumab during a third year correlates with reduced mean foveal thickness (FTH) and improved best-corrected visual acuity (BCVA), according ...

Adalimumab relieves hidradenitis suppurativa

December 18, 2012
(HealthDay)—For patients with moderate-to-severe hidradenitis suppurativa (HS), a chronic skin disease characterized by painful abscesses, nodules, and draining fistulas in the axilla and groin, treatment with once-weekly ...

Topical treatment shows potential for infantile eczema

August 8, 2012
(HealthDay) -- Ten days of treatment with a cream containing 15(R/S)-methyl-lipoxin A4 (LXA4) is well tolerated and reduces the severity of infantile eczema, according to a study published online July 26 in the British Journal ...

Recommended for you

Study seeks to aid diagnosis, management of catatonia

December 11, 2017
Catatonia, a syndrome of motor, emotional and behavioral abnormalities frequently characterized by muscular rigidity and a trance-like mental stupor and at times manifesting with great excitement or agitation, can occur during ...

New compound stops progressive kidney disease in its tracks

December 7, 2017
Progressive kidney diseases, whether caused by obesity, hypertension, diabetes, or rare genetic mutations, often have the same outcome: The cells responsible for filtering the blood are destroyed. Reporting today in Science, ...

New Lyme disease tests could offer quicker, more accurate detection

December 7, 2017
New tests to detect early Lyme disease - which is increasing beyond the summer months -could replace existing tests that often do not clearly identify the infection before health problems occur.

Spinal tap needle type impacts the risk of complications

December 6, 2017
The type of needle used during a lumbar puncture makes a significant difference in the subsequent occurrence of headache, nerve irritation and hearing disturbance in patients, according to a study by Hamilton medical researchers.

Men with HPV are 20 times more likely to be reinfected after one year

December 5, 2017
A new analysis of genital human papillomavirus (HPV) in men shows that infection with one HPV type strongly increases the risk of reinfection with the same type. In fact, men who are infected with the type responsible for ...

New tuberculosis drugs possible with understanding of old antibiotic

December 5, 2017
Tuberculosis, and other life-threatening microbial diseases, could be more effectively tackled with future drugs, thanks to new research into an old antibiotic by the University of Warwick and The Francis Crick Institute.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.